Chemo for Smoldering Multiple Myeloma? Not Yet!by definition—so it will take a lot of really good-quality days later to and smoldering multiplemyeloma based on multiparameter flow cytometry analysis of bone marrow plasma dexamethasone as initial therapy for newly diagnosed mu...
For patients with relapsed or refractory multiple myeloma, combination treatment with elotuzumab, lenalidomide, and low-dose dexamethasone is generally well tolerated, with encouraging response rates, according to a study published online April 30 in theJournal of Clinical Oncology. (HealthDay) -- For ...
Multiple myeloma (MM) is an incurable hematologic malignancy for which autologous hematopoietic stem cell transplantation (HCT) is a standard therapy. The optimal method of stem cell mobilization is not defined. We evaluated intravenous melphalan (60 mg/m), the most effective agent for MM, and G...
How long does multiple myeloma stay in remission? How long does it take for ovarian cancer to spread? What is the survival rate of metastatic breast cancer? Can breast cancer be cured? How fast can breast cancer grow? How effective is chemotherapy for bladder cancer?
In multiple myeloma (MM) blood-borne malignant plasma cells home to bone marrow (BM), where they accumulate in close contact with stromal cells. Nevertheless, the mechanisms responsible for MM cell chemotaxis are still poorly defined. In the present study we explored the mechanisms involved in th...
Chemotherapy serves as a main treatment strategy for acute myeloid leukemia (AML), a neoplastic cancer characterized by the accumulation of aberrant immature cells in the bone marrow (BM). To prevent AML relapse, increasing attention is being paid to leukemia cells that can survive chemotherapy. ...
This strategy can be applied for the treatment of several types of cancer, including lymphoma, leukemia, liver cancer carcinoma of prostate, intestine cancer, myeloma tumor, lymphoma, breast carcinoma, and ovarian cancer [34]. In a study conducted by Quan et al. [35], the authors designed a...
Expanding Access to Bispecifics in R/R Multiple Myeloma Treatment Real-World Outcomes of Oral Azacitidine Maintenance in AML Presented at ASH 2024 AI's Role in Differentiating MDS and Pre-MDS at ASH 2024 Exciting Advances in AML Treatment: Jain on Key Highlights for ASH 2024 A Step Forward...
Kaklamani on Elacestrant for CDK4/6 Inhibitor-Naive ER+ Breast Cancer Treatment T-DXd in ER+/HER2-Low Breast Cancer: Insights From DESTINY-Breast06 Expanding Access to Bispecifics in R/R Multiple Myeloma Treatment Real-World Outcomes of Oral Azacitidine Maintenance in AML Present...
In fact, according toa review inCancerspublished last year, more than 100 of these cancer-fighting antibodies are currently in clinical development. However,two recently presentedantibody-drug conjugates could help treat breast cancer and multiple myeloma. They’ve already shown good success in help...